Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
用户EO9nReo4Hj6s
1个月前
108
10
已完结
1. 系统已在2026-04-29 13:41:53对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s1470-2045(26)00049-5
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S1470204526000495
其他信息:
出版社: Elsevier BV
作者: Hua Zhong; Jing Wang; Runxiang Yang; Yongzhong Luo; Wei Zuo; Wei Zhang; Chao Xie; Qingshan Li; Qiang Liu; Xingxiang Xu; Qiming Wang; Yan Yu; Yongxing Chen; Tienan Yi; Xuhong Min; Jinsheng Shi; Jian Yang; Hongmei Sun; Hualin Chen; Huaqiu Shi; Junzhen Gao; Jianhua Shi; Bo Zhang; Tianqing Chu; Kai Li; Baohui Han
